SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending with intense anticipation for its Phase 3 REGAL trial results, as the extended timeline is widely seen by the community as a positive indicator of 'curative outcomes' and a potential buyout. Investors are largely dismissing bearish sentiment and focusing on increasing institutional interest and the transformative potential of the company's dual cancer platforms.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following multiple analyst upgrades with significantly higher price targets and anticipation around management's comments on stabilizing the BetterHelp segment and addressing debt. The community is actively debating its extreme undervaluation compared to sector peers and its strong free cash flow, fueling speculation of a potential short squeeze amid optimism for its global virtual care platform and AI initiatives.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting a significant Q4 earnings beat driven by strong MIPLYFFA sales, which is signaling a shift to profitability and sparking community discussions about its re-rating potential and a possible short squeeze.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is actively discussed amid conflicting reports on the Middle East conflict; bulls eye a "Trump pump" after claims of the war being "pretty much done," while bears highlight rising oil prices and Iranian denials, fueling concerns of manipulation and a market reversal.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

CHAC is trending as its merger target, Xanadu Quantum Technologies, announced a significant collaboration with AMD to accelerate quantum computing for aerospace and engineering, fueling community excitement over its real-world applications and strong client roster. Investors are actively watching the anticipated merger, with many adding the pure-play photonic quantum computing leader to their watchlists and discussing its potential compared to past successful SPACs in the burgeoning sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending following its announcement of a proposed convertible senior notes offering, which has sparked community concern over potential dilution and questions regarding management's capital strategy despite significant existing cash reserves. Many are expressing frustration, especially in contrast to positive developments from its partner, Vertex Pharmaceuticals.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is actively discussed after announcing a merger with U.S. defense prime contractor Mistral Inc., a move many view as a transformative step providing direct access to significant Department of Defense programs and expanding its role in the autonomous defense market. While bulls are enthusiastic about this strategic positioning, community dialogue also reflects concerns regarding potential share dilution from the all-stock deal and its immediate impact on stock performance ahead of upcoming earnings.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending following a mixed earnings report that saw an EPS beat but a revenue miss and cautious forward guidance, sparking debate among investors. Bulls are highlighting strengthened cash flow and the company's underlying real estate value, while bears point to soft sales and the challenging retail landscape, all amplified by significant short interest.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending down significantly following its reported quarterly loss and a weaker outlook, coupled with the announcement that its co-founders plan to leave to start a new mRNA company. Despite this, positive Phase 3 oncology data and a major analyst upgrade are sparking community debate, with many investors viewing the sharp decline as a buying opportunity given the company's substantial cash reserves and focused cancer pipeline.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as a recent business update indicates building commercial momentum for its gene therapy ZEVASKYN, with strong patient identification and expanding qualified treatment centers, fueling community optimism for profitability by Q2. This comes amidst multiple analyst upgrades reinforcing the belief that the stock is currently undervalued, despite some acknowledging the launch has progressed slower than initially expected.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AT&T's $250 Billion Bet On US Telecom's Future

AT&T rose in Tuesday premarket trading after reaffirming major U.S. network investment plans and upbeat 2026 guidance, though technical signals still suggest mixed near-term momentum.read more...

NYSE Content Update: AT&T CEO John Stankey to Ring Bell on 150th Anniversary of First Phone Call

NYSE Content Update: AT&T CEO John Stankey to Ring Bell on 150th Anniversary of First Phone Call NYSE Content Update: AT&T CEO John Stankey to Ring Bell on 150th Anniversary of First Phone Call PR...

AT&T Inc. $T Shares Bought by Capital Research Global Investors

Capital Research Global Investors grew its holdings in AT&T Inc. (NYSE:T - Free Report) by 0.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange...

Legal & General Group Plc Increases Stock Holdings in AT&T Inc. $T

Legal & General Group Plc lifted its position in shares of AT&T Inc. (NYSE:T - Free Report) by 1.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission...

<ul class="summary-bullets"><li>AT&amp;T said its partnership with AST SpaceMobile is expected to extend mobile connectivity to areas where traditional networks struggle to reach.</li><li>The telecom provider will also upgrade its public-safety infrastructure, including improvements to FirstNet.</li><li>The company plans to recruit thousands of additional technicians, including large hiring rounds in 2026.&nbsp;</li></ul>AT&amp;T Inc. (T) on Tuesday unveiled an ambitious plan to invest more than $250 billion over the next five years to expand and modernize its communications infrastructure across the United States.&nbsp;The multiyear funding push will focus on expanding fiber internet, 5G wireless coverage, and satellite-supported connectivity to meet growing demand for reliable digital access in cities, suburbs and rural regions.&nbsp;<h2 class="st-heading-2">Expanding Nationwide Connectivity</h2>The company said its partnership with AST SpaceMobile is expected to extend mobile connectivity to areas where traditional networks struggle to reach.&nbsp;<blockquote>"Today, we're committing more than $250 billion to increase U.S. connectivity competitiveness and expand access to AT&amp;T's leading ﬁber and wireless networks – the best way to get on the internet.”-John Stankey, Chairman and CEO, AT&amp;T</blockquote><a href="https://stocktwits.com/symbol/T">AT&amp;T stock</a> inched 0.6% lower in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory while message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Building For The Next Digital Era</h2>The telecom provider said it is also upgrading its public-safety infrastructure, including improvements to FirstNet, the dedicated network created for emergency responders.AT&amp;T said it is strengthening network security through its “Dynamic Defense” platform while introducing customer-focused features such as Wi-Fi personalization and enhanced data performance at crowded events.The company mentioned that tuning its communications networks is essential for technologies that rely on massive-scale data processing, such as AI-powered applications, smart infrastructure systems, and connected transportation.AT&amp;T currently employs about 110,000 people in the U.S. and plans to recruit thousands of additional technicians, including large hiring rounds in 2026.&nbsp;T stock has gained 0.9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-bntx-stock-tumble-pre-market-today/cZdoYZmRIey">Why Did BNTX Stock Tumble 17% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 AT&T store, building exterior, Fifth Avenue, New York City, New York, USA. 

AT&T Is Spending $250B On Connectivity In The US – Here’s Where The Money Is Going 

The telecom giant plans to deploy the funds over the next five years to scale fiber internet, 5G wireless networks and satellite connectivity.

Equity

AT&T Announces $250 Bln Commitment To Increase U.S. Connectivity

(RTTNews) - AT&T (T) announced an investment and spend of more than $250 billion in the future of U.S. advanced connectivity, building the high-speed networks and resilience required for the next...

AT&T Celebrates 150 years of Connecting on the Anniversary of the First Telephone Call

AT&T Celebrates 150 years of Connecting on the Anniversary of the First Telephone Call AT&T Celebrates 150 years of Connecting on the Anniversary of the First Telephone Call PR Newswire DALLAS, March...

AT&T Announces $250 Billion Commitment to Advance U.S. Connectivity

AT&T Announces $250 Billion Commitment to Advance U.S. Connectivity AT&T Announces $250 Billion Commitment to Advance U.S. Connectivity PR Newswire DALLAS, March 10, 2026 DALLAS, March 10, 2026...

Bank of Montreal Can Has $327.50 Million Stock Position in AT&T Inc. $T

Bank of Montreal Can lifted its holdings in shares of AT&T Inc. (NYSE:T - Free Report) by 3.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and...

Rep. David Taylor Sells Off Shares of AT&T Inc. (NYSE:T)

Representative David Taylor (Republican-Ohio) recently sold shares of AT&T Inc. (NYSE:T). In a filing disclosed on March 06th, the Representative disclosed that they had sold between $1,001 and...

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

Iran / Geopolitical tensions

Fed speakers

Macro data

Earnings

What will be the primary market driver this week?

Stocktwits

Stocktwits Polls

AT&T Inc

The company announced a massive $250 billion investment through 2030 to enhance U.S. fiber, 5G, home internet, and satellite infrastructure.

Traders are questioning why the stock is down significantly today following the announcement of a major $250 billion investment plan.

The vast network investment is aimed at building critical conduits that will enable next-gen Artificial Intelligence and autonomous technologies.

T
AT&T Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest T News

TAT&T Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest T News

T
AT&T Inc